⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1098210 | 0.78 | — | — | |
| SCHEMBL19112764 | 0.76 | GAA (0.42) | — | |
| SCHEMBL9352370 | 0.76 | — | — | |
| SCHEMBL4761672 | 0.76 | — | — | |
| SCHEMBL18507052 | 0.74 | BRD4 (0.39) | — | |
| SCHEMBL7114325 | 0.74 | — | — | |
| SCHEMBL19083668 | 0.69 | — | — | |
| SCHEMBL20329604 | 0.67 | — | — | |
| SCHEMBL19083669 | 0.67 | GAA (0.40) | — | |
| SCHEMBL18779 | 0.67 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024151547-A1 | TARGETED DEGRADATION OF VAV1 | MONTE ROSA THERAPEUTICS, INC. (US) | 2024-07-18 | — | — | WO | disclosed |
| WO-2024123999-A1 | TREATMENT OF GRAFT-VERSUS-HOST DISEASE WITH INHIBITORS OF BET FAMILY BDII BROMODOMAIN | POSEIDON INNOVATION 1, INC. (US) | 2024-06-13 | — | — | WO | disclosed |
| US-10428083-B2 | Heterocyclylmethyl-thienouracile as antagonists of the adenosine-A2B-receptor | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2019-10-01 | — | — | US | disclosed |
| US-20180065981-A1 | HETEROCYCLYLMETHYL-THIENOURACILE AS ANTAGONISTS OF THE ADENOSINE-A2B-RECEPTOR | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2018-03-08 | — | — | US | disclosed |
| EP-2909192-B1 | METHYLENE LINKED QUINOLINYL MODULATORS OF ROR-GAMMA-T | JANSSEN PHARMACEUTICA NV (BE) | 2017-05-17 | — | — | EP | disclosed |
| US-20080161278-A1 | 2-Azetidinyl-4-(1H-Pyrazol-3-Ylamino) Pyrimidines as Inhibitors of Insulin-Like Growth Factor-1 Receptor Activity | ASTRAZENECA AB (SE) | 2008-07-03 | — | — | US | disclosed |
| EP-0232623-B1 | 1-CARBACEPHALOSPORIN ANTIBIOTICS | ELI LILLY AND COMPANY (US) | 1993-03-17 | — | — | EP | disclosed |
| US-4892942-A | 1-CARBA (DETHIA)CEPHALOSPORINS | ELI LILLY AND COMPANY (US) | 1990-01-09 | — | — | US | disclosed |
| US-4791106-A | 1-Carbacephalosporin antibiotics | ELI LILLY AND COMPANY (US) | 1988-12-13 | — | — | US | disclosed |
| EP-0232623-A1 | 1-Carbacephalosporin antibiotics | ELI LILLY AND COMPANY (US) | 1987-08-19 | — | — | EP | disclosed |
| EP-0060120-B1 | PROCESS FOR PREPARING 4-HALOAZETIDIN-2-ONES | ELI LILLY AND COMPANY (US) | 1984-12-19 | — | — | EP | disclosed |
| US-4368156-A | USING POSITIVE HALOGEN REAGENT | ELI LILLY AND COMPANY (US) | 1983-01-11 | — | — | US | disclosed |
| EP-0060120-A1 | Process for preparing 4-haloazetidin-2-ones | ELI LILLY AND COMPANY (US) | 1982-09-15 | — | — | EP | disclosed |